MissionIR Articles
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Spring 2021 Oncology Investor Conference
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its plans to participate in two virtual investor conferences in the month of March.…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it has created a Clinical Advisory Board (“CAB”). The company has named world-renowned medical…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it joins with millions of healthcare advocates around the world in support of World Cancer Day. The designation…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has achieved a significant milestone for its REQORSA(TM) Immunogene Therapy. The company has met…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures $12M in Registered Direct Offering
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor. The agreement outlines…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced its completion of the manufacturing scale-up of REQORSA(TM) immunogene therapy. Subject to satisfactory completion of final testing currently underway,…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Finalizes Technology Transfer of Manufacturing Process for Novel Gene Therapy
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Overview, Clinical Trial Update at Upcoming Benzinga Conference
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will present at the Benzinga Global Small Cap Conference taking place virtually on Dec. 8-9, 2020. Genprex’s…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Upcoming Acclaim-1 Clinical Trial
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, on Monday announced its commencement of clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Diamond Equity Research Emerging Growth Invitational
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will participate at the Diamond Equity Research Emerging Growth Invitational taking place…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Life Sciences Summit Panel
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its senior vice president of intellectual property and licensing, Thomas Gallagher, will participate…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the addition of George K. Gittes, MD to its Scientific Advisory Board (“SAB”). According…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Launch of New Branding for Upcoming Combination Clinical Trials
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the launch of new branding for its upcoming oncology clinical trials. The trials combine Genprex’s lead…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial